Double hit and double expressors in lymphoma: Definition and treatment
The DOI matches its Crossref record; 55 of the 55 references it cites were found in a registry or an index.
Abstract
Emerging biologic subsets and new prognostic markers are significantly and adversely affecting curability after standard chemoimmunotherapy for aggressive B‐cell lymphomas. The identification of concurrent MYC and B‐cell CLL/lymphoma 2 (BCL2) deregulation, whether at a genomic or protein level, has opened a new era of investigation within the most common subtype of aggressive B‐cell lymphomas. Double‐hit lymphoma (DHL), defined as a dual rearrangement of MYC and BCL2 and/or B‐cell CLL/lymphoma 6 ( BCL6 ) genes, is an uncommon subset accounting for 5% to 7% of all diffuse large B‐cell lymphomas (DLBCLs), and long‐term survivors are rare. Double‐expressor lymphoma (DEL), defined as overexpression of MYC and BCL2 proteins not related to underlying chromosomal rearrangements, is not a distinct entity in the current World Health Organization classification but accounts for 20% to 30% of DLBCL cases and also has poor outcomes. There are many practical considerations related to identifying, determining the prognosis of, and managing DHL and DEL.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling
Alizadeh, A. A., Eisen, M. B., Davis, R. E., Ma, C., Lossos, I. S., Rosenwald, A., Boldrick, J. C., Sabet, H., Tran, T., Yu, X., et al. (2000) · Nature · doi:10.1038/35000501 · Cited by 9,925 · cited 10×
“The MYC-IG rearrangement is the hallmark of BL and serves as a defining characteristic in approximately 60% of HGBL cases and in a minority of cases of DLBCL.1,15-17 However, in approximately 5% of DLBCL cases, MYC rearrangements may involve a non-IG partner such as BCL6, BCL11A, or PAX5.”
MethodInfluentialThe 2016 revision of the World Health Organization classification of lymphoid neoplasms
Swerdlow, S. H., Campo, E., Pileri, S. A., Harris, N. L., Stein, H., Siebert, R., Advani, R., Ghielmini, M., Salles, G. A., Zelenetz, A. D., et al. (2016) · Blood · doi:10.1182/blood-2016-01-643569 · Cited by 7,831
Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell Lymphoma
Neelapu, S. S., Locke, F. L., Bartlett, N. L., Lekakis, L. J., Miklos, D. B., Jacobson, C. A., Braunschweig, I., Oluwole, O. O., Siddiqi, T., Lin, Y., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1707447 · Cited by 6,030 · cited 1×
“CAR T cells targeting the CD19 moiety have demonstrated potent clinical activity in patients with chemotherapy-refractory DLBCL and in patients relapsing after ASCT, including patients with durable complete remissions lasting more than 2 years.(71,72) Current data suggest that this therapy is equally effective in both…”
Backgroundp53-dependent apoptosis modulates the cytotoxicity of anticancer agents
Lowe, S. W., Ruley, H. E., Jacks, T., & Housman, D. E. (1993) · Cell · doi:10.1016/0092-8674(93)90719-7 · Cited by 2,925 · cited 1×
“TP53 mutations have been found in 20% to 30% of patients with DHL and are thought to contribute to the negative prognosis of this entity.(47,48) In a study by Gebauer et al,(47) TP53 mutations were found to be more common in MYC/BCL2 DHL in comparison with classic DLBCL or DHL with MYC/BCL6 rearrangements.”
BackgroundChimeric Antigen Receptor T Cells in Refractory B-Cell Lymphomas
Schuster, S. J., Svoboda, J., Chong, E. A., Nasta, S. D., Mato, A. R., Anak, Ö., Brogdon, J. L., Pruteanu-Malinici, I., Bhoj, V., Landsburg, D., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1708566 · Cited by 1,860 · cited 2×
“Current data suggest that this therapy is equally effective in both the double-hit and double-expressor subsets, although more mature data are needed to better delineate long-term outcomes.(72) In October 2017, axicabtagene ciloleucel (Kite Pharma, Santa Monica, California) was Food and Drug Administration–approved fo…”
BackgroundResultGisselbrecht, C., Glass, B., Mounier, N., Singh Gill, D., Linch, D. C., Trneny, M., Bosly, A., Ketterer, N., Shpilberg, O., Hagberg, H., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2010.28.1618 · Cited by 1,625 · cited 1×
“mab, dexamethasone, high-dose cytarabine, and cisplatin (R-DHAP) salvage regimens.(68) Within the context of this study, MYC-rearranged DLBCL patients exhibited”
BackgroundReflecting on 25 years with MYC
Meyer, N., & Penn, L. Z. (2008) · Nature Reviews Cancer · doi:10.1038/nrc2231 · Cited by 1,575 · cited 2×
“4623 Cancer December 15, 2018 proliferation and oncogenesis.(8) The spectrum of MYC effects appears dependent on the histologic context; for example, transcriptional targets in Burkitt lymphoma (BL) are completely distinct from transcriptional targets in DLBCL even though they share an identical t(8;14) rearrangement.”
BackgroundMolecular subtypes of diffuse large B-cell lymphoma arise by distinct genetic pathways
Lenz, G., Wright, G. W., Emre, N. C. T., Kohlhammer, H., Dave, S. S., Davis, R. E., Carty, S., Lam, L. T., Shaffer, A. L., Xiao, W., et al. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0804295105 · Cited by 995 · cited 11×
“The MYC-IG rearrangement is the hallmark of BL and serves as a defining characteristic in approximately 60% of HGBL cases and in a minority of cases of DLBCL.1,15-17 However, in approximately 5% of DLBCL cases, MYC rearrangements may involve a non-IG partner such as BCL6, BCL11A, or PAX5.”
BackgroundMethodInfluentialJohnson, N. A., Slack, G. W., Savage, K. J., Connors, J. M., Ben-Neriah, S., Rogic, S., Scott, D. W., Tan, K. L., Steidl, C., Sehn, L. H., et al. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2011.41.0985 · Cited by 975 · cited 1×
“comes in comparison with those with DHL with concurrent dual protein expression.(15,35)”
ResultMolecular Diagnosis of Burkitt's Lymphoma
Dave, S. S., Fu, K., Wright, G. W., Lam, L. T., Kluin, P., Boerma, E.-J., Greiner, T. C., Weisenburger, D. D., Rosenwald, A., Ott, G., et al. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa055759 · Cited by 897 · cited 1×
“The spectrum of MYC effects appears dependent on the histologic context; for example, transcriptional targets in Burkitt lymphoma (BL) are completely distinct from transcriptional targets in DLBCL even though they share an identical t(8;14) rearrangement.(12) In general, MYC rearrangements are strongly associated with…”
BackgroundGreen, T. M., Young, K. H., Visco, C., Xu-Monette, Z. Y., Orazi, A., Go, R. S., Nielsen, O., Gadeberg, O. V., Mourits-Andersen, T., Frederiksen, M., et al. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2011.41.4342 · Cited by 686 · cited 4×
“One proposed approach involves limiting FISH analysis to only certain cases on the basis of an initial immunohistochemical analysis, with the overlying rationale being that the vast majority of DHL cases (>90%) are of the GCB subtype.(43) Thus, pathologic specimens could first be screened for GCB derivation; if we ass…”
BackgroundMethodInfluentialThe BCL6 proto-oncogene suppresses p53 expression in germinal-centre B cells
Phan, R. T., & Dalla-Favera, R. (2004) · Nature · doi:10.1038/nature03147 · Cited by 679
Hu, S., Xu-Monette, Z. Y., Tzankov, A., Green, T., Wu, L., Balasubramanyam, A., Liu, W.-M., Visco, C., Li, Y., Miranda, R. N., et al. (2013) · Blood · doi:10.1182/blood-2012-10-460063 · Cited by 679 · cited 4×
“In summary, the ideal procedure would be to screen all patients with aggressive B-cell lymphomas for DHL at diagnosis, particularly because of the profound negative impact on outcomes and poor OS.”
BackgroundInfluentialSavage, K. J., Johnson, N. A., Ben-Neriah, S., Connors, J. M., Sehn, L. H., Farinha, P., Horsman, D. E., & Gascoyne, R. D. (2009) · Blood · doi:10.1182/blood-2009-05-220095 · Cited by 660
Lymphomas with concurrent BCL2 and MYC translocations: the critical factors associated with survival
Johnson, N. A., Savage, K. J., Ludkovski, O., Ben-Neriah, S., Woods, R., Steidl, C., Dyer, M. J. S., Siebert, R., Kuruvilla, J., Klasa, R., et al. (2009) · Blood · doi:10.1182/blood-2009-03-212191 · Cited by 587
Diagnosing and exploiting cancer's addiction to blocks in apoptosis
Letai, A. G. (2008) · Nature Reviews Cancer · doi:10.1038/nrc2297 · Cited by 580 · cited 1×
“In the setting of malignant lymphoma, BCL2 overexpression is synergistic with MYC and other oncogenes and promotes the progression of lymphoma and resistance to chemotherapy.(28,29) BCL2 dysregulation can be seen as a result of chromosomal translocations and gene amplification and has also been linked with increased n…”
BackgroundPeyrade, F., Jardin, F., Thieblemont, C., Thyss, A., Emile, J.-F., Castaigne, S., Coiffier, B., Haioun, C., Bologna, S., Fitoussi, O., et al. (2011) · The Lancet Oncology · doi:10.1016/s1470-2045(11)70069-9 · Cited by 553
Barrans, S., Crouch, S., Smith, A., Turner, K., Owen, R., Patmore, R., Roman, E., & Jack, A. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.26.3947 · Cited by 552 · cited 2×
“In light of such considerations and because DHL is seen in only 5% to 12% of DLBCL cases, many centers have adopted a more tailored approach with respect to FISH analysis, although such algorithms are not without limitations.(52,53) One proposed approach involves limiting FISH analysis to only certain cases on the bas…”
BackgroundHorn, H., Ziepert, M., Becher, C., Barth, T. F. E., Bernd, H.-W., Feller, A. C., Klapper, W., Hummel, M., Stein, H., Hansmann, M.-L., et al. (2013) · Blood · doi:10.1182/blood-2012-06-435842 · Cited by 542 · cited 1×
“4624 Cancer December 15, 2018 is likely attributable to gene amplification and posttranslational processes in the absence of chromosomal translocations.(30,36,37) An increased MYC copy number or gene amplification can also occur in 8% to 20% of DLBCL cases, although its impact on prognosis is less clear.”
BackgroundLenz, G., & Staudt, L. M. (2010) · New England Journal of Medicine · doi:10.1056/nejmra0807082 · Cited by 528
Germinal centres and B cell lymphomagenesis
Basso, K., & Dalla-Favera, R. (2015) · Nature Reviews Immunology · doi:10.1038/nri3814 · Cited by 510 · cited 10×
“The MYC-IG rearrangement is the hallmark of BL and serves as a defining characteristic in approximately 60% of HGBL cases and in a minority of cases of DLBCL.1,15-17 However, in approximately 5% of DLBCL cases, MYC rearrangements may involve a non-IG partner such as BCL6, BCL11A, or PAX5.”
MethodInfluentialHoffman, B., & Liebermann, D. A. (2008) · Oncogene · doi:10.1038/onc.2008.312 · Cited by 488
Petrich, A. M., Gandhi, M., Jovanovic, B., Castillo, J. J., Rajguru, S., Yang, D. T., Shah, K. A., Whyman, J. D., Lansigan, F., Hernandez-Ilizaliturri, F. J., et al. (2014) · Blood · doi:10.1182/blood-2014-05-578963 · Cited by 467 · cited 5×
“CNS-directed prophylaxis with intrathecal chemotherapy has been associated with a decreased incidence of CNS progression, although there is a paucity of data comparing this approach with systemic high-dose methotrexate (HDMTX) therapy.(46,51) In patients at high risk for CNS relapse, HDMTX can be safely administered m…”
BackgroundResultInfluentialSelf-citationRoles of BCL6 in normal and transformed germinal center B cells
Basso, K., & Dalla‐Favera, R. (2012) · Immunological Reviews · doi:10.1111/j.1600-065x.2012.01112.x · Cited by 429
The epidemiology of non-Hodgkin's lymphoma
Fisher, S. G., & Fisher, R. I. (2004) · Oncogene · doi:10.1038/sj.onc.1207843 · Cited by 425 · cited 1×
“Diffuse large B-cell lymphoma (DLBCL) is increasingly being recognized as a very heterogeneous disease that can be characterized by distinct pathologic subtypes, morphologic variants, and gene expression profiles.(1,2) In most DLBCL cases, standard-of-care chemoimmunotherapy with rituximab, cyclophosphamide, doxorubic…”
BackgroundBasso, K., & Dalla-Favera, R. (2010) · Advances in Immunology · doi:10.1016/s0065-2776(10)05007-8 · Cited by 302
Copie-Bergman, C., Cuillière-Dartigues, P., Baia, M., Briere, J., Delarue, R., Canioni, D., Salles, G., Parrens, M., Belhadj, K., Fabiani, B., et al. (2015) · Blood · doi:10.1182/blood-2015-05-647602 · Cited by 255
Abramson, J. S., Hellmann, M. D., Barnes, J. A., Hammerman, P. S., Toomey, C. E., Takvorian, T., Muzikansky, A., & Hochberg, E. P. (2010) · Cancer · doi:10.1002/cncr.25278 · Cited by 252 · cited 5×
“The authors concluded that unlike DHL with MYC/BCL2 rearrangements, concurrent MYC/BCL6 rearrangements were not associated with inferior outcomes in patients treated with R-CHOP.”
BackgroundInfluentialValera, A., Lopez-Guillermo, A., Cardesa-Salzmann, T., Climent, F., Gonzalez-Barca, E., Mercadal, S., Espinosa, I., Novelli, S., Briones, J., Mate, J. L., et al. (2013) · Haematologica · doi:10.3324/haematol.2013.086173 · Cited by 229
Savage, K. J. J., Slack, G. W., Mottok, A., Sehn, L. H., Villa, D. R., Kansara, R. R., Kridel, R., Steidl, C., Ennishi, D., Tan, K. L., et al. (2016) · Blood · doi:10.1182/blood-2015-10-676700 · Cited by 212 · cited 1×
“Similarly, patients with DEL demonstrated a 10% risk of CNS relapse at 2 years that was independent of the COO or CNS-IPI score.(63) Patients not receiving methotrexate-based CNS prophylaxis have much shorter survival.”
BackgroundLeonard, J. P., Kolibaba, K. S., Reeves, J. A., Tulpule, A., Flinn, I. W., Kolevska, T., Robles, R., Flowers, C. R., Collins, R., DiBella, N. J., et al. (2017) · Journal of Clinical Oncology · doi:10.1200/jco.2017.73.2784 · Cited by 186 · cited 1×
“In most DLBCL cases, standard-of-care chemoimmunotherapy with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) results in variable cure rates, but the average is approximately 70%.(3,4) The curability of DLBCL is heavily influenced by a number of factors, including the age, International…”
BackgroundHerrera, A. F., Mei, M., Low, L., Kim, H. T., Griffin, G. K., Song, J. Y., Merryman, R. W., Bedell, V., Pak, C., Sun, H., et al. (2017) · Journal of Clinical Oncology · doi:10.1200/jco.2016.68.2740 · Cited by 185 · cited 1×
“comes in comparison with those with DHL with concurrent dual protein expression.(15,35)”
ResultOutcomes of Patients With Double-Hit Lymphoma Who Achieve First Complete Remission
Landsburg, D. J., Falkiewicz, M. K., Maly, J. J., Blum, K. A., Howlett, C., Feldman, T. A., Mato, A. R., Hill, B. T., Li, S., Medeiros, L. J., et al. (2017) · Journal of Clinical Oncology · doi:10.1200/jco.2017.72.2157 · Cited by 181
Howlett, C., Snedecor, S. J., Landsburg, D. J., Svoboda, J., Chong, E. A., Schuster, S. J., Nasta, S. D., Feldman, T., Rago, A., Walsh, K. M., et al. (2015) · British Journal of Haematology · doi:10.1111/bjh.13463 · Cited by 177 · cited 1×
“032), although no difference in OS was noted.(57) On the basis of these data, more intensified induction chemotherapy has frequently been adopted, with R-EPOCH often being the regimen of choice because of a more favorable toxicity profile in comparison with other intensive regimens.”
BackgroundThe Role of c-MYC in B-Cell Lymphomas: Diagnostic and Molecular Aspects
Nguyen, L., Papenhausen, P., & Shao, H. (2017) · Genes · doi:10.3390/genes8040116 · Cited by 177 · cited 1×
“Increased expression of the MYC protein can occur as a result of multiple mechanisms, including chromosomal translocations, MYC gene amplification, mutations within the gene, and copy number alterations.(13,14) Both the precise mechanism of MYC dysregulation and the presence of mutations within the MYC gene influence…”
BackgroundBCL2 mutations in diffuse large B-cell lymphoma
Schuetz, J. M., Johnson, N. A., Morin, R. D., Scott, D. W., Tan, K. X., Neriah, S. B., Boyle, M., Slack, G. W., Marra, M. A., Connors, J. M., et al. (2011) · Leukemia · doi:10.1038/leu.2011.378 · Cited by 171 · cited 2×
“BCL2 dysregulation can be seen as a result of chromosomal translocations and gene amplification and has also been linked with increased nuclear factor B signaling.(30)”
BackgroundCuccuini, W., Brière, J., Mounier, N., Voelker, H.-U., Rosenwald, A., Sundström, C., Cogliatti, S., Hirchaud, E., Ysebaert, L., Bron, D., et al. (2012) · Blood · doi:10.1182/blood-2012-01-406033 · Cited by 170
Aukema, S. M., Kreuz, M., Kohler, C. W., Rosolowski, M., Hasenclever, D., Hummel, M., Kuppers, R., Lenze, D., Ott, G., Pott, C., et al. (2014) · Haematologica · doi:10.3324/haematol.2013.091827 · Cited by 169
Bertrand, P., Bastard, C., Maingonnat, C., Jardin, F., Maisonneuve, C., Courel, M.-N., Ruminy, P., Picquenot, J. M., & Tilly, H. (2007) · Leukemia · doi:10.1038/sj.leu.2404529 · Cited by 161
Targeting BCL2 for the Treatment of Lymphoid Malignancies
Anderson, M. A., Huang, D., & Roberts, A. (2014) · Seminars in Hematology · doi:10.1053/j.seminhematol.2014.05.008 · Cited by 149 · cited 1×
“In normal lymphoid cells, oxidative stress, genomic instability, and other insults induce the expression of the BH3 family of proteins, which function to inhibit BCL2 and thus allow apoptosis to proceed.(27) In the setting of malignant lymphoma, BCL2 overexpression is synergistic with MYC and other oncogenes and promo…”
BackgroundSwerdlow, S. H. (2014) · Hematology · doi:10.1182/asheducation-2014.1.90 · Cited by 149 · cited 2×
“In light of such considerations and because DHL is seen in only 5% to 12% of DLBCL cases, many centers have adopted a more tailored approach with respect to FISH analysis, although such algorithms are not without limitations.(52,53) One proposed approach involves limiting FISH analysis to only certain cases on the bas…”
BackgroundOverexpression of MYC causes p53 -dependent G 2 arrest of normal fibroblasts
Felsher, D. W., Zetterberg, A., Zhu, J., Tlsty, T., & Bishop, J. M. (2000) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.190327097 · Cited by 137
MYC Alterations in Diffuse Large B-Cell Lymphomas
Karube, K., & Campo, E. (2015) · Seminars in Hematology · doi:10.1053/j.seminhematol.2015.01.009 · Cited by 124 · cited 1×
“4624 Cancer December 15, 2018 is likely attributable to gene amplification and posttranslational processes in the absence of chromosomal translocations.(30,36,37) An increased MYC copy number or gene amplification can also occur in 8% to 20% of DLBCL cases, although its impact on prognosis is less clear.”
BackgroundYe, Q., Xu-Monette, Z. Y., Tzankov, A., et al. (2015) · Oncotarget · doi:10.18632/oncotarget.6262 · Cited by 116
Wilson, W. H., Jung, S., Pitcher, B. N., Hsi, E. D., Friedberg, J. W., Cheson, B. D., Bartlett, N. L., Smith, S. E., Johnston, N. W., Kahl, B. S., et al. (2016) · Blood · doi:10.1182/blood.v128.22.469.469 · Cited by 112
Self-citationBcl-2 Mediates Chemoresistance in Matched Pairs of Primary Eμ-myc Lymphomas in Vivo
Schmitt, C. A., & Lowe, S. W. (2001) · Blood Cells Molecules and Diseases · doi:10.1006/bcmd.2000.0372 · Cited by 105 · cited 1×
“In the setting of malignant lymphoma, BCL2 overexpression is synergistic with MYC and other oncogenes and promotes the progression of lymphoma and resistance to chemotherapy.(28,29) BCL2 dysregulation can be seen as a result of chromosomal translocations and gene amplification and has also been linked with increased n…”
BackgroundWang, X. J., Medeiros, L. J., Bueso-Ramos, C., Tang, G., Wang, S., Oki, Y., Desai, P. A., Khoury, J. D., Miranda, R. N., Tang, Z., et al. (2016) · Modern Pathology · doi:10.1038/modpathol.2016.178 · Cited by 100
Landsburg, D. J., Petrich, A. M., Abramson, J. S., Sohani, A. R., Press, O. W., Cassaday, R. D., Chávez, J. C., Song, K., Zelenetz, A. D., Gandhi, M. D., et al. (2015) · Cancer · doi:10.1002/cncr.29781 · Cited by 87 · cited 1×
“MYC with BCL6, and the remaining 21% of patients have all 3 rearrangements (THL).(34) Notably, up to 20%”
BackgroundSewastianik, T., Prochorec‐Sobieszek, M., Chapuy, B., & Juszczyński, P. (2014) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2014.08.006 · Cited by 75 · cited 1×
“Increased expression of the MYC protein can occur as a result of multiple mechanisms, including chromosomal translocations, MYC gene amplification, mutations within the gene, and copy number alterations.(13,14) Both the precise mechanism of MYC dysregulation and the presence of mutations within the MYC gene influence…”
BackgroundLandsburg, D. J., Falkiewicz, M. K., Petrich, A. M., Chu, B. A., Behdad, A., Li, S., Medeiros, L. J., Cassaday, R. D., Reddy, N. M., Bast, M. A., et al. (2016) · British Journal of Haematology · doi:10.1111/bjh.14282 · Cited by 69
Self-citationGebauer, N., Bernard, V., Gebauer, W., Thorns, C., Feller, A. C., & Merz, H. (2014) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.3109/10428194.2014.907896 · Cited by 67
Lu, T., Fan, L., Wang, L., Wu, J., Kourong, M., Liang, J., Gong, Q., Wang, Z., Young, K. H., Xu, W., et al. (2015) · Oncotarget · doi:10.18632/oncotarget.4073 · Cited by 66 · cited 1×
“An increased MYC copy number or gene amplification can also occur in 8% to 20% of DLBCL cases, although its impact on prognosis is less clear.(22,23,38) Landsburg et al(26) compared outcomes among 22 patients with MYC-amplified lymphoma, 87 patients with single-hit lymphoma, and 127 patients without MYC amplification…”
BackgroundCell-of-Origin in Diffuse Large B-Cell Lymphoma: Are the Assays Ready for the Clinic?
Scott, D. W. (2015) · American Society of Clinical Oncology Educational Book · doi:10.14694/edbook_am.2015.35.e458 · Cited by 64 · cited 1×
“Because immunohistochemistry is more commonly used to assess COO than gene expression profiling, the terms have evolved to GCB DLBCL and non-GCB DLBCL (which includes both ABC DLBCL and other non-GCB samples).(42) With respect to COO, 80% to 90% of DHL cases occur with GCB DLBCL.”
The prognosis of MYC translocation positive diffuse large B‐cell lymphoma depends on the second hit
Clipson, A., Barrans, S., Zeng, N., Crouch, S., Grigoropoulos, N. F., Liu, H., Kocialkowski, S., Wang, M., Huang, Y., Worrillow, L. J., et al. (2015) · The Journal of Pathology Clinical Research · doi:10.1002/cjp2.10 · Cited by 62
Quesada, A. E., Medeiros, L. J., Desai, P. A., Lin, P., Westin, J. R., Hawsawi, H. M., Wei, P., Tang, G., Seegmiller, A. C., Reddy, N. M., et al. (2017) · Modern Pathology · doi:10.1038/modpathol.2017.93 · Cited by 55
Metadata
- Authors
- Riedell, P. A., & Smith, S. M.
- Venue
- Cancer
- Publisher
- Wiley
- Published
- 2018-09-25
- Volume
- 124
- Issue
- 24
- Pages
- 4622-4632
- ISSN
- 0008-543X (ISSN-L)
- 1097-0142
- OpenAlex
- W2894196895
- Cited by
- 215
- References
- 55
- FWCI
- 9.32
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.